Thiopurine methyltransferase

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Thiopurine S-methyltransferase

PDB rendering based on 2bzg.
Identifiers
Symbols TPMT;
External IDs OMIM187680 MGI98812 HomoloGene313 GeneCards: TPMT Gene
EC number 2.1.1.67
RNA expression pattern
PBB GE TPMT 203671 at tn.png
PBB GE TPMT 203672 x at tn.png
More reference expression data
Orthologs
Species Human Mouse
Entrez 7172 22017
Ensembl ENSG00000137364 ENSMUSG00000021376
UniProt P51580 O55060
RefSeq (mRNA) NM_000367.2 NM_016785.2
RefSeq (protein) NP_000358.1 NP_058065.2
Location (UCSC) Chr 6:
18.13 – 18.16 Mb
Chr 13:
47.12 – 47.14 Mb
PubMed search [1] [2]
Thiopurine methyltransferase, drawn from PDB 2BZG.

Thiopurine methyltransferase or thiopurine S-methyltransferase (TPMT) is an enzyme (EC 2.1.1.67) that methylates thiopurine compounds. The methyl donor is S-adenosyl-L-methionine, which is converted to S-adenosyl-L-homocysteine.

This enzyme metabolizes thiopurine drugs via S-adenosyl-L-methionine as the S-methyl donor and S-adenosyl-L-homocysteine as a byproduct. Thiopurine drugs such as 6-mercaptopurine are used as chemotherapeutic agents. Genetic polymorphisms that affect this enzymatic activity are correlated with variations in sensitivity and toxicity to such drugs within individuals. A pseudogene for this locus is located on chromosome 18q.[1]

Contents

[edit] Pharmacology

TPMT is best known for its role in the metabolism of the thiopurine drugs such as azathioprine, 6-mercaptopurine and 6-thioguanine. TPMT catalyzes the S-methylation of thiopurine drugs. Defects in the TPMT gene leads to decreased methylation and decreased inactivation of 6MP leading to enhanced bone marrow toxicity which may cause myelosuppression, anemia, bleeding tendency, leukopenia & infection.[2]

[edit] Diagnostic use

Measurement of TPMT activity is encouraged prior to commencing the treatment of patients with thiopurine drugs such as azathioprine, 6-mercaptopurine and 6-thioguanine.; as patients with low activity (10% prevalence) or especially absent activity (prevalence 0.3%) are at a heightened risk of drug-induced bone marrow toxicity due to accumulation of the unmetabolised drug. Reuther et al. found that about 5% of all thiopurine therapies will fail due to toxicity. This intolerant group could be anticipated by routine measurement of TPMT activity. There appears to be a great deal of variation in TPMT mutation, with ethnic differences in mutation types accounting for variable responses to 6MP.[3]

[edit] References

[edit] Further reading

[edit] External links


Personal tools
Namespaces
Variants
Actions
Navigation
Interaction
Toolbox
Print/export
Languages